Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-11
2007-12-11
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S224000
Reexamination Certificate
active
11357494
ABSTRACT:
Compounds of formulae I and II:are disclosed as 5-HT3inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.
REFERENCES:
patent: 3850950 (1974-11-01), Amuller et al.
patent: 6403791 (2002-06-01), Dyke et al.
patent: 6828330 (2004-12-01), Walker et al.
patent: 2004/0132790 (2004-07-01), Xie et al.
patent: EP 0 507 637 (1992-04-01), None
patent: WO 92/15593 (1992-09-01), None
patent: WO 9822460 (1998-05-01), None
patent: WO0158896 (2001-08-01), None
patent: WO 02/051821 (2002-07-01), None
patent: WO 03/037896 (2003-05-01), None
patent: WO 03037896 (2003-05-01), None
patent: WO 2004/016600 (2004-02-01), None
Lesch et al. Biol. Psychiatry 1998; vol. 44, pp. 179-192.
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jul. 4, 2006, International Application No. PCT/US2006/005605, Applicant: AMR Technology, Inc.
Kumar et al., “Synthesis and Evaluation of Anticancer Benzoxazoles and Benzimidazoles related to UK-1”,Bioorganic&Medicinal Chemistry, 10 (2002) 3997-4004.
Denny et al, “Structure-activity relationships for the mutagenic activity of tricyclic intercalatine agents inSalmonella typhimurium”, Mutation Research, 232 (1990) 233-241.
Seshadri et al., “Synthesis of naphthoxazole derivatives by the application of the Vilsmeier-Haack reaction. Part II. 2-Hetarylnaphth[1,2-d]oxazole derivatives”,Dyes and Pigments, 8(6) (1987), 405-16.
Kusumi et al, “Structures of novel antibiotics boxazomycins A, B and C”,Tennen Yuki Kagobutsu Toronkai Koen Yoshishu, 28th (1986) 49-56 Coden: Tykyds.
Israili, Zafar H., “Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists”,Curr. Med. Chem, 1, (2001), 171-199.
Fairfax David J.
Yang Zhicai
AMR Technology , Inc.
Cheng Karen
Hansen Philip E.
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
Benzoxazole carboxamides for treating CINV and IBS-D does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazole carboxamides for treating CINV and IBS-D, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazole carboxamides for treating CINV and IBS-D will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892220